123 results on '"P. Hilliquin"'
Search Results
2. Assessing respiratory epidemic potential in French hospitals through collection of close contact data (April–June 2020)
- Author
-
George Shirreff, Bich-Tram Huynh, Audrey Duval, Lara Cristina Pereira, Djillali Annane, Aurélien Dinh, Olivier Lambotte, Sophie Bulifon, Magali Guichardon, Sebastien Beaune, Julie Toubiana, Elsa Kermorvant-Duchemin, Gerard Chéron, Hugues Cordel, Laurent Argaud, Marion Douplat, Paul Abraham, Karim Tazarourte, Géraldine Martin-Gaujard, Philippe Vanhems, Delphine Hilliquin, Duc Nguyen, Guillaume Chelius, Antoine Fraboulet, EMAE-MESuRS Working Group on Nosocomial SARS-CoV-2 Modelling, Laura Temime, Lulla Opatowski, and Didier Guillemot
- Subjects
Medicine ,Science - Abstract
Abstract The transmission risk of SARS-CoV-2 within hospitals can exceed that in the general community because of more frequent close proximity interactions (CPIs). However, epidemic risk across wards is still poorly described. We measured CPIs directly using wearable sensors given to all present in a clinical ward over a 36-h period, across 15 wards in three hospitals in April-June 2020. Data were collected from 2114 participants and combined with a simple transmission model describing the arrival of a single index case to the ward to estimate the risk of an outbreak. Estimated epidemic risk ranged four-fold, from 0.12 secondary infections per day in an adult emergency to 0.49 per day in general paediatrics. The risk presented by an index case in a patient varied 20-fold across wards. Using simulation, we assessed the potential impact on outbreak risk of targeting the most connected individuals for prevention. We found that targeting those with the highest cumulative contact hours was most impactful (20% reduction for 5% of the population targeted), and on average resources were better spent targeting patients. This study reveals patterns of interactions between individuals in hospital during a pandemic and opens new routes for research into airborne nosocomial risk.
- Published
- 2024
- Full Text
- View/download PDF
3. Concordance and agreement between different activity scores in polymyalgia rheumatica
- Author
-
Bruno Fautrel, Eric Toussirot, Renaud Felten, Emmanuel Nowak, Christophe Richez, Jacques-Eric Gottenberg, Isabelle Chary-Valckenaere, Alain Saraux, Aleth Perdriger, Emanuelle Dernis, Thierry Marhadour, Marie-Elise Truchetet, Divi Cornec, Valérie Devauchelle-Pensec, Daniel Wendling, Guillaume Direz, Anne Lohse, Laurent Chiche, PASCAL HILLIQUIN, Guillermo Carvajal Alegria, Dewi Guellec, Justine D'Agostino, Aghiles Souki, Catherine Le Henaff, and Benjamin Dervieux
- Subjects
Medicine - Abstract
Objective The C reactive protein polymyalgia rheumatica activity score (CRP-PMR-AS) is a composite index that includes CRP levels and was developed specifically for PMR. As treatments such as interleukin-6 antagonists can normalise CRP levels, the erythrocyte sedimentation rate (ESR) of PMR-AS, the clinical (clin)-PMR-AS and the imputed-CRP (imp-CRP)-PMR-AS have been developed to avoid such bias. Our primary objective was to measure the correlation of these activity scores. Our secondary objective was to evaluate the concordance between different cutoffs of the PMR-ASs.Method Data from the Safety and Efficacy of tocilizumab versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence (SEMAPHORE) trial, a superiority randomised double-blind placebo-controlled trial, were subjected to post hoc analysis to compare the efficacy of tocilizumab versus placebo in patients with active PMR. The CRP-PMR-AS, ESR-PMR-AS, clin-PMR-AS and imp-CRP-PMR-AS were measured at every visit. The concordance and correlation between these scores were evaluated using kappa correlation coefficients, Bland-Altman correlations, intraclass correlation coefficients (ICCs) and scatter plots.Results A total of 101 patients were included in the SEMAPHORE trial, and 100 were analysed in this study. The correlation between the PMR-ASs was excellent, as the ICC and kappa were >0.85 from week 4 until week 24 (CRP-PMR-AS ≤10 or >10). Bland-Altman plots revealed that the differences between the CRP-PMR-AS and the other threescores were low. The cut-off values for the clin-PMR-AS were similar to those for the CRP-PMR-AS 86% of the time.Conclusion The correlation between all the PMR-ASs was excellent, reflecting the low weight of CRP. In clinical trials using drugs that have an impact on CRP, the derived activity scores can be used.Trial registration number NTC02908217.
- Published
- 2024
- Full Text
- View/download PDF
4. Real-World 1-Year Retention Rate of Subcutaneous Tocilizumab Treatment in Patients with Moderate to Severe Active Rheumatoid Arthritis: TANDEM Study
- Author
-
Hilliquin, Pascal, Barnetche, Thomas, Baillet, Athan, Flipo, René-Marc, Lespessailles, Eric, Roux, Christian, Fardellone, Patrice, Gilbert-Marceau, Anika, Idier, Isabelle, Constantin, Arnaud, Shipley, Emilie, Baudens, Guy, and Saraux, Alain
- Published
- 2021
- Full Text
- View/download PDF
5. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study
- Author
-
Eric Toussirot, Hubert Marotte, Denis Mulleman, Grégoire Cormier, Fabienne Coury, Philippe Gaudin, Emmanuelle Dernis, Christine Bonnet, Richard Damade, Jean-Luc Grauer, Tassadit Ait Abdesselam, Caroline Guillibert-Karras, Frédéric Lioté, Pascal Hilliquin, Antoinette Sacchi, Daniel Wendling, Benoît Le Goff, Marc Puyraveau, and Gilles Dumoulin
- Subjects
Adiponectin ,Cardiovascular risk ,Rheumatoid arthritis ,Tocilizumab ,Body composition ,Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background Patients with rheumatoid arthritis (RA) have an increased risk of cardiovascular (CV) disease. Adiponectin is involved in the metabolism of glucose and lipids with favourable effects on CV disease, especially its high molecular weight (HMW) isoform. Body composition changes are described in RA with various phenotypes including obesity. The effects of tocilizumab on serum adiponectin and body composition, especially fat mass, in patients with RA are not well determined. Methods Patients with active RA despite previous csDMARDs and/or bDMARDs and who were tocilizumab naïve were enrolled in a multicentre open-label study. They were evaluated at baseline, 1, 3, 6 and 12 months. Clinical assessment included body mass index (BMI) and anthropometric measurements. Lipid and metabolic parameters, serum adiponectin (total and HMW), leptin, resistin and ghrelin were measured at each time point. Body composition (lean mass, fat mass, % fat, fat in the android and gynoid regions) was evaluated at baseline, 6 and 12 months. Results One hundred seven patients were included. Both total and HMW adiponectin significantly increased from baseline to month 3, peaking respectively at month 3 (p = 0.0105) and month 1 (p
- Published
- 2020
- Full Text
- View/download PDF
6. Impact of Early Conventional Treatment on Adult Bone and Joints in a Murine Model of X-Linked Hypophosphatemia
- Author
-
Axelle Cauliez, Volha V. Zhukouskaya, Stéphane Hilliquin, Jérémy Sadoine, Lotfi Slimani, Corinne Miceli-Richard, Karine Briot, Agnès Linglart, Catherine Chaussain, and Claire Bardet
- Subjects
rickets ,osteomalacia ,Hyp mice ,phosphorus ,conventional treatment ,XLH ,Biology (General) ,QH301-705.5 - Abstract
X-linked hypophosphatemia (XLH) is the most common form of genetic rickets. Mainly diagnosed during childhood because of growth retardation and deformities of the lower limbs, the disease affects adults with early enthesopathies and joint structural damage that significantly alter patient quality of life. The conventional treatment, based on phosphorus supplementation and active vitamin D analogs, is commonly administered from early childhood to the end of growth; unfortunately, it does not allow complete recovery from skeletal damage. Despite adequate treatment during childhood, bone and joint complications occur in adults and become a dominant feature in the natural history of the disease. Our previous data showed that the Hyp mouse is a relevant model of XLH for studying early enthesophytes and joint structural damage. Here, we studied the effect of conventional treatment on the development of bone and joint alterations in this mouse model during growth and young adulthood. Mice were supplemented with oral phosphorus and calcitriol injections, following two timelines: (i) from weaning to 3 months of age and (ii) from 2 to 3 months to evaluate the effects of treatment on the development of early enthesophytes and joint alterations, and on changes in bone and joint deformities already present, respectively. We showed that early conventional treatment improved bone microarchitecture, and partially prevented bone and joint complications, but with no noticeable improvement in enthesophytes. In contrast, later administration had limited efficacy in ameliorating bone and joint alterations. Despite the improvement in bone microarchitecture, the conventional treatment, early or late, had no effect on osteoid accumulation. Our data underline the usefulness of the Hyp murine model for preclinical studies on skeletal and extraskeletal lesions. Although the early conventional treatment is important for the improvement of bone microarchitecture, the persistence of osteomalacia implies seeking new therapeutic strategies, in particular anti-FGF23 approach, in order to optimize the treatment of XLH.
- Published
- 2021
- Full Text
- View/download PDF
7. Factors associated with admission to intensive care units in COVID-19 patients in Lyon-France.
- Author
-
Philippe Vanhems, Marie-Paule Gustin, Christelle Elias, Laetitia Henaff, Cédric Dananché, Béatrice Grisi, Elodie Marion, Nagham Khanafer, Delphine Hilliquin, Sophie Gardes, Solweig Gerbier-Colomban, Selilah Amour, Elisabetta Kuczewski, Vanessa Escuret, Bruno Lina, Mitra Saadatian-Elahi, and COVID-Outcomes-HCL Consortium
- Subjects
Medicine ,Science - Abstract
IntroductionA new respiratory virus, SARS-CoV-2, has emerged and spread worldwide since late 2019. This study aims at analysing clinical presentation on admission and the determinants associated with admission in intensive care units (ICUs) in hospitalized COVID-19 patients.Patients and methodsIn this prospective hospital-based study, socio-demographic, clinical and biological characteristics, on admission, of adult COVID-19 hospitalized patients presenting from the community for their first admission were prospectively collected and analysed. Characteristics of patients hospitalized in medical ward to those admitted in ICU were compared using Mann-Whitney and Chi-square or Fisher exact test when appropriate. Univariate logistic regression was first used to identify variables on admission that were associated with the outcome i.e. admission to an ICU versus total hospital stay in a medical ward. Forward selection was then applied beginning with sex, age and temperature in the multivariable logistic regression model.ResultsOf the 412 patients included, 325 were discharged and 87 died in hospital. Multivariable regression showed increasing odds of ICU hospitalization with temperature (OR, 1.56 [95% CI, 1.06-2.28] per degree Celsius increase), oxygen saturation 100mg/L vs CRPConclusionsAge and delay between onset of symptoms and hospital admission were associated with the risk of hospitalisation in ICU. Age being a fixed variable, interventions that shorten this delay would improve the prognosis of Covid-19 patients.
- Published
- 2021
- Full Text
- View/download PDF
8. Increased high molecular weight adiponectin and lean mass during tocilizumab treatment in patients with rheumatoid arthritis: a 12-month multicentre study
- Author
-
Toussirot, Eric, Marotte, Hubert, Mulleman, Denis, Cormier, Grégoire, Coury, Fabienne, Gaudin, Philippe, Dernis, Emmanuelle, Bonnet, Christine, Damade, Richard, Grauer, Jean-Luc, Abdesselam, Tassadit Ait, Guillibert-Karras, Caroline, Lioté, Frédéric, Hilliquin, Pascal, Sacchi, Antoinette, Wendling, Daniel, Le Goff, Benoît, Puyraveau, Marc, and Dumoulin, Gilles
- Published
- 2020
- Full Text
- View/download PDF
9. Surface Contamination by Antineoplastic Drugs in Two Oncology Inpatient Units
- Author
-
Palamini Marie, Hilliquin Delphine, Delisle Jean-François, Chouinard Audrey, and Bussières Jean-François
- Subjects
hazardous drugs ,trace contamination ,environmental surveillance ,occupational exposure ,Therapeutics. Pharmacology ,RM1-950 ,Pharmaceutical industry ,HD9665-9675 - Abstract
Hazardous drugs pose risks to health care workers. To reduce the risk of occupational exposure for all workers, several protective and monitoring measures have been recommended and implemented over the past two decades. This study was undertaken to describe traces contamination with ten antineoplastic drugs in the oncology care unit of two university hospitals.
- Published
- 2020
- Full Text
- View/download PDF
10. SARS-CoV-2 rapid test versus RT-qPCR on noninvasive respiratory self-samples during a city mass testing campaign.
- Author
-
Gagnaire, Julie, Bonjean, Paul, Verot, Elise, Boulamail, Billal, Labetoulle, Remi, Gonzalo, Sylvie, Hilliquin, Delphine, Pillet, Sylvie, Michaud, Patrick, Brebion, Amélie, Morfin, Florence, Goff, Jérôme Le, Pelissier, Carole, Bourlet, Thomas, group, AutoCov study, Chauvin, Franck, Berthelot, Philippe, Botelho-Nevers, Elisabeth, and Pozzetto, Bruno
- Published
- 2022
- Full Text
- View/download PDF
11. Association and Expression Study of PRKCH Gene in a French Caucasian Population with Rheumatoid Arthritis
- Author
-
Teixeira, Vitor Hugo, Jacq, Laurent, Moore, Jeoiakim, Lasbleiz, Sandra, Hilliquin, Pascal, Resende Oliveira, Catarina, Cornelis, François, and Petit-Teixeira, Elisabeth
- Published
- 2008
- Full Text
- View/download PDF
12. HSPD1 is not a major susceptibility gene for rheumatoid arthritis in the French Caucasian population
- Author
-
Jacq, Laurent, Teixeira, Vitor Hugo, Garnier, Sophie, Michou, Laëtitia, Dieudé, Philippe, Rocha, Dominique, Pierlot, Céline, Lemaire, Isabelle, Quillet, Patrick, Hilliquin, Pascal, Mbarek, Hamdi, Petit-Teixeira, Elisabeth, and Cornélis, François
- Published
- 2007
- Full Text
- View/download PDF
13. Characterisation of Patients with Postmenopausal Osteoporosis in French Primary Healthcare
- Author
-
Blotman, Francis, Cortet, Bernard, Hilliquin, Pascal, Avouac, Bernard, Allaert, François-André, Pouchain, Denis, Gaudin, Anne-Françoise, Cotté, François-Emery, and El Hasnaoui, Abdelkader
- Published
- 2007
- Full Text
- View/download PDF
14. Transcriptome analysis describing new immunity and defense genes in peripheral blood mononuclear cells of rheumatoid arthritis patients.
- Author
-
Vitor Hugo Teixeira, Robert Olaso, Marie-Laure Martin-Magniette, Sandra Lasbleiz, Laurent Jacq, Catarina Resende Oliveira, Pascal Hilliquin, Ivo Gut, François Cornelis, and Elisabeth Petit-Teixeira
- Subjects
Medicine ,Science - Abstract
BACKGROUND: Large-scale gene expression profiling of peripheral blood mononuclear cells from Rheumatoid Arthritis (RA) patients could provide a molecular description that reflects the contribution of diverse cellular responses associated with this disease. The aim of our study was to identify peripheral blood gene expression profiles for RA patients, using Illumina technology, to gain insights into RA molecular mechanisms. METHODOLOGY/PRINCIPAL FINDINGS: The Illumina Human-6v2 Expression BeadChips were used for a complete genome-wide transcript profiling of peripheral blood mononuclear cells (PBMCs) from 18 RA patients and 15 controls. Differential analysis per gene was performed with one-way analysis of variance (ANOVA) and P values were adjusted to control the False Discovery Rate (FDR
- Published
- 2009
- Full Text
- View/download PDF
15. Tetracyclines inhibit nitrosothiol production by cytokine-stimulated osteoarthritic synovial cells
- Author
-
Borderie, D., Hernvann, A., Hilliquin, P., Lemarchal, H., Kahan, A., and Ekindjian, O.G.
- Published
- 2001
- Full Text
- View/download PDF
16. Cohorting for preventing the nosocomial spread of Carbapenemase-Producing Enterobacterales, in non-epidemic settings: is it mandatory?
- Author
-
Hilliquin, D., Lomont, A., Zahar, J-R., Hilliquin, Delphine, Lomont, Alexandra, and Zahar, Jean-Ralph
- Abstract
Background: Worldwide dissemination of Carbapenemase-Producing Enterobacterales (CPE) has led to national and international guidance recommending the implementation of cohorting in healthcare settings (HS). However, in view of recent data regarding the spread of Extended-spectrum Beta-lactamase-producing Enterobacterales, we may wonder about the usefulness of this measure in a non-outbreak settings; here, individual contact isolation may be sufficient to control the risk of dissemination.Aim/methods: We conducted a narrative review of the literature and discussed the role of cohorting.Findings: CPE are responsible for outbreaks in HS, which are considered the epicentre of spread of resistance strains. CPE are responsible for adverse effects such as increases in hospital stay and costs, less therapeutic options and thus higher risk of clinical failures and mortality. Environment and materials have also been described contaminated with CPE and can be the source of outbreak. Even if guidelines and publications have supported implementation of cohorting, there are no randomized studies demonstrating the mandatory nature of this measure. Most studies are descriptive and cohorting is usually one of several other measures to control outbreaks. Cohorting is not adapted to all HS, which requires human and material resources. Other measures must be strengthened such as compliance of hand hygiene, antibiotic stewardship and surveillance of contact patients. Individual risk factors of acquisition should also be evaluated.Conclusion: Local epidemiology and resources must be assessed before implementing cohorting. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
17. Production of PAF-acether by synovial fluid neutrophils in rheumatoid arthritis
- Author
-
Hilliquin, P., Dulioust, A., Gregoir, C., Arnoux, A., and Menkès, C. J.
- Published
- 1995
- Full Text
- View/download PDF
18. Comparison of general practitioners and rheumatologists' prescription patterns for patients with knee osteoarthritis
- Author
-
Carni Paolo, Bertin Philippe, Hilliquin Pascal, Richette Pascal, Berger Véronique, and Marty Marc
- Subjects
Diseases of the musculoskeletal system ,RC925-935 - Abstract
Abstract Background To compare the prescription modalities of general practitioners (GPs) and rheumatologists (RHs) for symptomatic knee osteoarthritis (OA) and to determine correlates with prescription of low-dose NSAIDs. Methods This observational, prospective, national survey was carried out among a national representative sample of GPs (n = 808) and RHs (n = 134). Each physician completed a medical questionnaire for the 2 most recent patients fulfilling the ACR criteria for knee OA. Results GPs and RHs included 1,570 and 251 patients, respectively. Mean pain level of the knee (on a VAS, 0-100 mm) was greater for GP patients than for RH patients (49.8 ± 16.3 vs. 46.2 ± 17.1 mm, respectively; p < 0.01). As compared with patients of RHs, those of GPs more frequently had another joint affected by OA: 71.2% vs. 63.7% (p < 0.0001) and more often had hypertension and diabetes mellitus (p < 0.05). As compared with RHs, GPs more frequently prescribed low-dose NSAIDs (p < 0.0001), oral NSAIDs (p < 0.05), and topical NSAIDs (p < 0.0001) but less frequently symptomatic slow-acting drugs for OA (p < 0.01). Moreover, GPs more frequently recommended rehabilitation (p < 0.01) and loss of weight (p < 0.0001). Logistic regression analysis revealed an association of low-dose NSAIDs prescription and prescription by GPs, prescription of topical NSAIDs, no prescription of oral NSAIDs or coxibs and no intra-articular injection of steroids. Conclusions This study identified speciality-related variability in some aspects of the management of knee OA. The clinical profile of patients with knee OA differed between GPs and RHs.
- Published
- 2011
- Full Text
- View/download PDF
19. Is cohorting the only solution to control carbapenemase-producing Enterobacteriaceae outbreaks? A single-centre experience.
- Author
-
Legeay, C., Thépot-Seegers, V., Pailhoriès, H., Hilliquin, D., and Zahar, J.-R.
- Abstract
Background: Carbapenemase-producing Enterobacteriaceae (CPE) are a major health issue. Cohorting may help to control spread of CPEs in hospitals, but is expensive and hard to implement.Aim: To identify ward variables associated with CPE in-hospital transmission in a hospital where cohorting has never been implemented.Methods: Cohort prospective study, comparing 14-consecutive-day periods regarding in-hospital transmission. Each period met the two following conditions: (i) CPE carriers/infected admitted for ≥48 h; (ii) 80% of relative contact patients were screened at least twice. Periods (a) with no acquired CPE case among relative contact patients were compared to periods (b) during which one or more CPE case acquisition was identified. Variables potentially associated with CPE transmission were assessed: colonization pressure, caregiver:patient ratio, hand hygiene compliance, hydro-alcoholic product consumption, antibiotic consumption, and infection control team (ICT) involvement on the ward.Findings: Sixty-eight periods of two consecutive weeks were included, 18 (26.5%) included at least one CPE case acquisition. By multivariate analysis, colonization pressure (odds ratio: 1.12; 95% confidence interval: 1.0-1.25; P = 0.042) and antibiotic consumption (2.41; 1.02-5.66; P = 0.044) were associated with CPE in-hospital transmission. Caregiver:patient ratio potentiated both these variables, suggesting a role for understaffing in CPE transmission.Conclusion: Understanding ward variables associated with CPE spread can help design suitable solutions. Colonization pressure and antibiotic consumption seems to be driving in-hospital transmission, along with caregiver:patient ratio. In presence of high colonization pressure, dedicated healthcare workers for managing CPE patients should be implemented. Co-ordination between ICT and antimicrobial stewardship team is also crucial to prevent CPE spread. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
20. Risk factors for acquisition of OXA-48-producing Klebsiella pneumonia among contact patients: a multicentre study.
- Author
-
Hilliquin, D., Le Guern, R., Thepot Seegers, V., Neulier, C., Lomont, A., Marie, V., Legeay, C., Merrer, J., Lepelletier, D., Rogues, A.M., Grandbastien, B., Lucet, J.C., and Zahar, J.R.
- Abstract
Background: Cohorting carbapenemase-producing Enterobacteriaceae (CPE) carriers during hospitalization limits in-hospital spreading.Aim: To identify risk factors for CPE acquisition among contacts of an index patient in non-cohorted populations.Methods: A multicentre retrospective matched case-control study was conducted in five hospitals. Each contact patient (case) who acquired Klebsiella pneumoniae (KP)-OXA-48 from an index patient was compared to three contact (controls) with the same index patients matched with hospitalization in the same unit and similar exposure times.Findings: Fifty-one secondary cases and 131 controls were included. By univariate analysis, exposure time (odds ratio: 1.06; 95% confidence interval: 1.02-1.1; P = 0.006), concomitant infection at admission (3.23; 1.42-7.35; P = 0.005), antimicrobial therapy within the last month before hospitalization (2.88; 1.34-6.2; P = 0.007), antimicrobial therapy during the exposure time (5.36; 2.28-12.6; P < 0.001), use of at least one invasive procedure (2.99; 1.25-7.15; P = 0.014), number of invasive procedures (1.52; 1.05-2.19; P = 0.025), and geographical proximity (2.84; 1.15-7.00; P = 0.023) were associated with CPE acquisition. By multivariate analysis, antimicrobial therapy during the exposure time (odds ratio: 6.36; 95% confidence interval: 2.46-16.44; P < 0.001), at least one invasive procedure (2.92; 1.04-8.17; P = 0.041), and geographical proximity (3.69; 1.15-11.86; P = 0.028) were associated with acquisition.Conclusion: In this study, geographical proximity, invasive procedure, and antimicrobial therapy during exposure time were significantly associated with KP-OXA-48 acquisition. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
21. Escherichia coli sécréteur de bêta-lactamase à spectre élargi, quelles mesures faut-il prendre pour maîtriser le risque ?
- Author
-
Hilliquin, Delphine, Lambert, Wayne, Legeay, Clément, Zahar, Jean-Ralph, and Grall, Isabelle
- Abstract
Résumé L’endémie d’entérobactéries sécrétrices de bêta-lactamase à spectre élargi (EBLSE) que nous vivons actuellement est liée à la diffusion d’un mécanisme de résistance plasmidique au sein des entérobactéries et particulièrement l’espèce Escherichia coli . Cette situation épidémiologique nécessite un niveau d’observance élevé des précautions standards et une maîtrise de la prescription antibiotique. D’autres mesures complémentaires peuvent être justifiées de par les données épidémiologiques locales. Lutter contre la diffusion de ce mécanisme de résistance est une priorité dans la mesure où sa diffusion fait le lit de la diffusion des Entérobactéries productrices de carbapénémase. Summary We are living an endemic situation related to the spread of ESBL-producing Enterobacteriaceae. To contain this phenomena we need a high compliance to hand hygiene and standard precautions associated with an efficient control of the antibiotic consumption. However local epidemiological data could justify additional measures. Our priority should be to combat the spread of ESBL-PE, as it is the first step before spreading of Carbapenemase producing enterobacteriaceae. [ABSTRACT FROM AUTHOR]
- Published
- 2016
- Full Text
- View/download PDF
22. Impact of faecal microbiota transplantation on mouse digestive colonization with two extensively resistant bacteria.
- Author
-
Mahieu, Rafael, Cassisa, Viviane, Hilliquin, Delphine, Coron, Noémie, Pailhoriès, Hélène, Kempf, Marie, Joly-Guillou, Marie-Laure, and Eveillard, Matthieu
- Published
- 2017
- Full Text
- View/download PDF
23. Genetic and expression analysis of CASP7 gene in a European Caucasian population with rheumatoid arthritis.
- Author
-
Teixeira VH, Jacq L, Lasbleiz S, Hilliquin P, Oliveira CR, Cornelis F, and Petit-Teixeira E
- Published
- 2008
24. External contamination of commercial containers by antineoplastic agents: a literature review.
- Author
-
Hilliquin, Delphine, Tanguay, Cynthia, and Bussières, Jean-François
- Published
- 2020
- Full Text
- View/download PDF
25. The Influence of the Definition of Patient Global Assessment in Assessment of Disease Activity According to the Disease Activity Score (DAS28) in Rheumatoid Arthritis.
- Author
-
DOUGADOS, MAXIME, RIPERT, MAHAUT, HILLIQUIN, PASCAL, FARDELLONE, PATRICE, BROCQ, OLIVIER, BRAULT, YVES, and LOGEART, ISABELLE
- Published
- 2011
- Full Text
- View/download PDF
26. 262: Use of allopurinol and risk of myocardial infarction: A case-control study.
- Author
-
Grimaldi-Bensouda, Lamiae, Alpérovitch, Annick, Aubrun, Elodie, Richette, Pascal, Hilliquin, Pascal, Danchin, Nicolas, Steg, Philippe-Gabriel, Fautrel, Bruno, Rossignol, Michel, and Abenhaim, Lucien
- Abstract
Background While gout is considered as a risk factor for vascular diseases, the relation of allopurinol with the risk of cardiovascular events is controversial. In some studies, drug use was associated with an increased vascular risk, while other studies described a protective effect. Objectives We conducted a case-control study to examine the relation between allopurinol use and risk of myocardial infarction (MI). Methods Cases (n=2277) were successive patients with a first-ever non-fatal MI referred to 63 cardiology centres throughout France between March 15, 2007 and November 30, 2010. They were matched to 4849 controls selected in a large (12,313) general practice patient referent population. Controls had no past history of coronary heart disease and were matched to MI cases on age, gender, number of visits to a doctor in the preceding year, date of consultation (MI) and past history of high blood pressure. Data about medication use during the two preceding years, and past medical history and life habits (smoking, physical activity, etc.) were obtained from patient's standardized interview and GP records. Odds ratios (OR) and their 95% confidence interval were computed using conditional logistic regression, adjusting for classical vascular risk factors (body mass index, smoking, diabetes, physical activity). Results MI cases and controls had a mean age of 59 years, 76% were men and 56% reported a history of high blood pressure. High body mass index, low physical activity, smoking and diabetes were more prevalent in cases than in controls. Overall, during the two preceding years, 3.8% of controls and 3.1% of MI cases had used allopurinol, and 1.1 of both cases and controls had used another hypouricemiant. Use of allopurinol was associated with a non-significant decreased risk of MI (adjusted OR (95%CI): 0.75 (0.56 - 1.01). Conclusions This study showed that allopurinol use is not a risk factor for first-ever non-fatal MI and might rather be associated with a decreased risk of MI. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
27. 144 EARLY DECREASE OF SERUM BIOMARKERS OF TYPE II COLLAGEN DEGRADATION (Coll2-l) AND JOINT INFLAMMATION (Coll2-lN02) BY HYALURONIC ACID INTRA-ARTICULAR INJECTIONS IN PATIENTS WITH KNEE OSTEOARTHRITIS.
- Author
-
Henrotin, Y., Conrozier, T., Deberg, M., Walliser-Lohse, A., Richette, P., Mulleman, D., Maillet, B., Rannou, F., Piroth, C., Hilliquin, P., and Chevalier, X.
- Published
- 2011
- Full Text
- View/download PDF
28. 365 MANAGEMENT OF KNEE OSTEOARTHRITIS: COMPARISON OF GENERAL PRACTITIONERS AND RHEUMATOLOGISTS' PRACTICES.
- Author
-
Richette, P., Hilliquin, P., Bertin, P., Carni, P., Savarieau, B., Berger, V., and Marty, M.
- Published
- 2009
- Full Text
- View/download PDF
29. Concordance and agreement between different activity scores in polymyalgia rheumatica.
- Author
-
D'Agostino J, Souki A, Lohse A, Carvajal Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, Toussirot E, Perdriger A, Gottenberg JE, Felten R, Fautrel B, Chiche L, Hilliquin P, Le Henaff C, Dervieux B, Direz G, Chary-Valckenaere I, Cornec D, Guellec D, Marhadour T, Nowak E, Saraux A, and Devauchelle-Pensec V
- Subjects
- Humans, Glucocorticoids therapeutic use, C-Reactive Protein metabolism, Blood Sedimentation, Polymyalgia Rheumatica diagnosis, Polymyalgia Rheumatica drug therapy, Giant Cell Arteritis
- Abstract
Objective: The C reactive protein polymyalgia rheumatica activity score (CRP-PMR-AS) is a composite index that includes CRP levels and was developed specifically for PMR. As treatments such as interleukin-6 antagonists can normalise CRP levels, the erythrocyte sedimentation rate (ESR) of PMR-AS, the clinical (clin)-PMR-AS and the imputed-CRP (imp-CRP)-PMR-AS have been developed to avoid such bias. Our primary objective was to measure the correlation of these activity scores. Our secondary objective was to evaluate the concordance between different cutoffs of the PMR-ASs., Method: Data from the Safety and Efficacy of tocilizumab versus Placebo in Polymyalgia rHeumatica With glucocORticoid dEpendence (SEMAPHORE) trial, a superiority randomised double-blind placebo-controlled trial, were subjected to post hoc analysis to compare the efficacy of tocilizumab versus placebo in patients with active PMR. The CRP-PMR-AS, ESR-PMR-AS, clin-PMR-AS and imp-CRP-PMR-AS were measured at every visit. The concordance and correlation between these scores were evaluated using kappa correlation coefficients, Bland-Altman correlations, intraclass correlation coefficients (ICCs) and scatter plots., Results: A total of 101 patients were included in the SEMAPHORE trial, and 100 were analysed in this study. The correlation between the PMR-ASs was excellent, as the ICC and kappa were >0.85 from week 4 until week 24 (CRP-PMR-AS ≤10 or >10). Bland-Altman plots revealed that the differences between the CRP-PMR-AS and the other threescores were low. The cut-off values for the clin-PMR-AS were similar to those for the CRP-PMR-AS 86% of the time., Conclusion: The correlation between all the PMR-ASs was excellent, reflecting the low weight of CRP. In clinical trials using drugs that have an impact on CRP, the derived activity scores can be used., Trial Registration Number: NTC02908217., Competing Interests: Competing interests: None declared., (© Author(s) (or their employer(s)) 2024. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ.)
- Published
- 2024
- Full Text
- View/download PDF
30. Changes of anti-citrullinated peptide antibodies titers after biologic treatment in patients with rheumatoid arthritis: a systematic literature review and retrospective study.
- Author
-
Hilliquin S, Herrou J, Gutermann L, Goulvestre C, Avouac J, Henry J, Hilliquin P, Dougados M, and Moltó A
- Subjects
- Humans, Female, Middle Aged, Male, Abatacept therapeutic use, Retrospective Studies, Rituximab therapeutic use, Anti-Citrullinated Protein Antibodies, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid drug therapy, Biological Products adverse effects
- Abstract
Objectives: There is an increasing body of evidence suggesting a direct pathophysiological role of anti-citrullinated peptide antibodies (ACPA) in rheumatoid arthritis (RA), and immunological remission could be a target for treatment. However, data related to the ability of biologics to reduce ACPA titres are contradictory.We aimed to evaluate the changes in ACPA titres after treatment with different biologics in patients with RA., Methods: As a first step, a systematic review of the literature available on 3 biologics (TNFi, abatacept and rituximab) and ACPA in patients with RA was performed in Pubmed and Cochrane. As a second step, a retrospective study was performed: all RA patients treated with the 3 above-mentioned biologics were identified. To be included in the analysis, patients had to have at least two titres of ACPA (one before and one after biologic treatment) available. ACPA titres were compared before and after treatment in each of the treatment groups., Results: As a result of the literature review, 24 articles were retained confirming that the data on change in ACPA under biologics is contradictory, particularly for abatacept and TNFi. 144 RA patients (79.3% female, mean age: 56 years) were included in the retrospective analysis: 59 patients had received rituximab, 31 abatacept, 55 TNFi. ACPA titres decreased significantly with rituximab but not with abatacept nor TNFi. Modelling of ACPA titres over follow-up confirmed the significant decrease of ACPA over time rituximab., Conclusions: In this real-life study, ACPA titres only significantly decreased after treatment with rituximab.
- Published
- 2023
- Full Text
- View/download PDF
31. Comparison of Biological Agent Monotherapy and Associations Including Disease-Modifying Antirheumatic Drugs for Rheumatoid Arthritis: Literature Review and Meta-Analysis of Randomized Trials.
- Author
-
Delpech C, Laborne FX, and Hilliquin P
- Abstract
Objective: Update the available evidence comparing biologic disease-modifying antirheumatic drugs (bDMARDs) in combination with conventional synthetic disease-modifying antirheumatic drugs (CsDMARDs) to bDMARDs in monotherapy in patients with rheumatoid arthritis., Methods: Research was limited to randomized controlled trials. Major outcome: ACR 20 response criteria at 24 weeks., Secondary Outcomes: clinical and radiographic criteria at week 24, 52 and 104., Results: 23 trials (6358 patients), including seven bDMARDs and one other molecule: Anbainuo (anti-TNF-R). No study satisfied our search criteria for anakinra, certolizumab and infliximab. Compared to bDMARD monotherapy, combination therapy gives a better ACR 20 at 24 weeks (RR: 0.88 (0.84-0.94)) in fixed and random effect models, and this result is sustained at 52 and 104 weeks. The results were mostly similar for all other outcomes without increasing the risk of adverse effects., Conclusion: This meta-analysis confirms the superiority of combination therapy over monotherapy in rheumatoid arthritis, in accordance to the usual guidelines.
- Published
- 2022
- Full Text
- View/download PDF
32. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
- Author
-
Devauchelle-Pensec V, Carvajal-Alegria G, Dernis E, Richez C, Truchetet ME, Wendling D, Toussirot E, Perdriger A, Gottenberg JE, Felten R, Fautrel BJ, Chiche L, Hilliquin P, Le Henaff C, Dervieux B, Direz G, Chary-Valckenaere I, Cornec D, Guellec D, Marhadour T, Nowak E, and Saraux A
- Subjects
- Administration, Intravenous, Administration, Oral, Aged, C-Reactive Protein analysis, Double-Blind Method, Drug Tapering, Female, Giant Cell Arteritis diagnosis, Giant Cell Arteritis drug therapy, Humans, Interleukin-6 antagonists & inhibitors, Male, Anti-Inflammatory Agents administration & dosage, Anti-Inflammatory Agents adverse effects, Anti-Inflammatory Agents therapeutic use, Antibodies, Monoclonal, Humanized administration & dosage, Antibodies, Monoclonal, Humanized therapeutic use, Glucocorticoids administration & dosage, Glucocorticoids adverse effects, Glucocorticoids therapeutic use, Polymyalgia Rheumatica diagnosis, Polymyalgia Rheumatica drug therapy, Prednisone administration & dosage, Prednisone adverse effects, Prednisone therapeutic use
- Abstract
Importance: Few treatments are available for patients with glucocorticoid-dependent polymyalgia rheumatica. IL-6 antagonists may reduce disease activity in patients with active glucocorticoid-dependent polymyalgia rheumatica., Objective: To compare the efficacy of tocilizumab vs placebo in patients with glucocorticoid-dependent polymyalgia rheumatica., Design, Setting, and Participants: This double-blind, parallel-group, placebo-controlled randomized clinical trial enrolled 101 patients with polymyalgia rheumatica at 17 hospitals in France from February 2017 to October 2019. Final follow-up occurred in November 2020. Inclusion criteria were persistent disease activity (polymyalgia rheumatica activity score computed using the C-reactive protein level [CRP PMR-AS] >10) and prednisone dose greater than or equal to 10 mg per day., Interventions: Patients were randomly assigned to receive intravenous tocilizumab (8 mg/kg; n = 51) or placebo (n = 50) every 4 weeks for 24 weeks, combined with predefined standardized tapering of oral prednisone., Main Outcomes and Measures: The primary efficacy end point was CRP PMR-AS less than 10 (range, 0-100; higher values indicate greater activity; no minimal clinically important difference defined) combined with either prednisone dose less than or equal to 5 mg per day or a decrease in prednisone dose greater than or equal to 10 mg from baseline at week 24. There were 11 secondary outcomes assessed at week 24 included in this report, including disease activity (measured by CRP PMR-AS) and the proportion of patients no longer taking prednisone., Results: Of the 101 randomized patients (mean age, 67.2 years; 68 [67.3%] women), 100 (99%) received at least 1 infusion and 100 completed the trial. The primary end point was achieved in 67.3% of patients in the tocilizumab group and 31.4% of patients in the placebo group (adjusted difference, 36.0% [95% CI, 19.4%-52.6%]; adjusted relative risk, 2.3 [95% CI, 1.5-3.6]; P < .001). Of 11 reported secondary end points at 24 weeks, 7 showed significant differences favoring tocilizumab, including mean CRP PMR-AS score (7.5 [95% CI, 5.4-9.6] vs 14.9 [95% CI, 11.4-18.4]; adjusted difference, -7.5 [95% CI, -11.2 to -3.8]; P < .001) and the percentage of patients no longer receiving prednisone (49.0% vs 19.6%; adjusted difference, 29.3% [95% CI, 18.9%-39.7%]; adjusted relative risk, 2.5 [95% CI, 1.8-3.5]; P < .001). The most frequent adverse events were infections, experienced by 23 patients (46.9%) in the tocilizumab group and 20 (39.2%) in the placebo group., Conclusions and Relevance: Among patients with active polymyalgia rheumatica despite prednisone therapy, tocilizumab, compared with placebo, resulted in a significantly greater percentage of patients with a CRP PMR-AS less than 10 with reduced prednisone requirements at week 24. Further research is needed to confirm efficacy and to determine the balance of potential benefits and harms., Trial Registration: ClinicalTrials.gov Identifier: NCT02908217.
- Published
- 2022
- Full Text
- View/download PDF
33. Two-year abatacept retention rate in clinical practice in the French ACTION cohort.
- Author
-
Mariette X, Schaeverbeke T, Gaudin P, Chartier M, Heitzmann J, Vannier-Moreau V, Hilliquin P, and Cantagrel A
- Subjects
- Adult, Aged, Body Mass Index, Cohort Studies, Dose-Response Relationship, Drug, Drug Administration Schedule, Female, Follow-Up Studies, France, Humans, Internationality, Male, Middle Aged, Patient Compliance statistics & numerical data, Prospective Studies, Rheumatoid Factor, Severity of Illness Index, Time Factors, Treatment Outcome, Abatacept administration & dosage, Antirheumatic Agents administration & dosage, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid drug therapy, Medication Adherence statistics & numerical data
- Abstract
Objectives: Abatacept retention rates were evaluated in the French cohort in the prospective ACTION study (2010-2013), which included patients with moderate-to-severe rheumatoid arthritis managed in everyday clinical practice and started on intravenous abatacept therapy., Methods: Two-year abatacept retention rates were evaluated in 455 patients classified according to treatment line, body mass index (BMI), and status for rheumatoid factor (RF) and anti-citrullinated peptide antibody (ACPA)., Results: After 2 years, the overall abatacept retention rate was 44%. The retention rate was non-significantly higher in the patients with vs. without a history of unresponsiveness to at least one biologic (48.1% vs. 41.8%, respectively). No significant retention rate differences were found across BMI categories (444 patients; <25, 45.5%; ≥25 to <30, 48.9%; and ≥30, 36.6%). Neither were any significant differences demonstrated according to RF and ACPA status (RF+ and ACPA+, 45.7%; RF+ or ACPA+, 43.8%; and FR- and ACPA-, 39.1%)., Conclusion: The 44% 2-year retention rate in the French ACTION cohort supports the usefulness of abatacept therapy. In this study, retention was not associated with treatment line, BMI, or antibody status., (Copyright © 2019 Société française de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.)
- Published
- 2019
- Full Text
- View/download PDF
34. Thrombotic microangiopathy associated with anti-neutrophil cytoplasmic antibody-associated vasculitis: a French nationwide retrospective case-control study and literature review.
- Author
-
Dellal A, Bige N, Hilliquin P, Boffa JJ, Rondeau E, Hatron PY, Deligny C, Bally S, Maury E, Veyradier A, Buob D, Fain O, Coppo P, and Mekinian A
- Subjects
- Adolescent, Adult, Aged, Case-Control Studies, Female, France epidemiology, Humans, Male, Middle Aged, Registries, Retrospective Studies, Thrombotic Microangiopathies immunology, Young Adult, Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis complications, Thrombotic Microangiopathies epidemiology
- Published
- 2019
- Full Text
- View/download PDF
35. Psoriatic arthritis screening by the dermatologist: development and first validation of the 'PURE-4 scale'.
- Author
-
Audureau E, Roux F, Lons Danic D, Bagot M, Cantagrel A, Dernis E, Gouyette N, Hilliquin P, Jullien D, Lioté F, Passeron T, A Richard M, and Claudepierre P
- Subjects
- Adult, Age Distribution, Area Under Curve, Cohort Studies, Female, France epidemiology, Humans, Incidence, Logistic Models, Male, Middle Aged, Predictive Value of Tests, Program Evaluation, Psoriasis diagnosis, Psoriasis epidemiology, ROC Curve, Retrospective Studies, Risk Assessment, Severity of Illness Index, Sex Distribution, Arthritis, Psoriatic diagnosis, Arthritis, Psoriatic epidemiology, Dermatologists, Early Diagnosis, Mass Screening organization & administration
- Abstract
Background: Dermatologists are recommended to ask psoriasis patients about musculoskeletal complaints to allow early detection and treatment of psoriatic arthritis (PsA). Screening tools have been developed to help identify patients warranting further rheumatologic assessment, but evidence suggests room for improvement in their diagnostic value and ease of use for outpatient practice., Objective: To develop and internally validate a brief tool for dermatologists to screen patients to refer to a rheumatologist for PsA diagnosis., Methods: After the literature review, 23 items were selected, covering pain at various locations and inflammatory signs of PsA. The validation study was conducted in medically diagnosed psoriasis patients consecutively recruited between 2012 and 2014 (Saint Joseph Hospital, Paris, France). Patients were enrolled by a dermatologist who helped to complete the questionnaire. Diagnosis of PsA was established by a rheumatologist based on CASPAR criteria. Multivariate logistic regression models were performed to build the scale, assessing discrimination through sensitivity, specificity and area under the ROC curve (AUC). Final model was internally validated using bootstrapping techniques., Results: One hundred and sixty-eight patients were recruited, of whom nine were excluded for known PsA and 21 did not attend the rheumatologist consultation. Of 137 included patients (median age 43 years, 59.6% men), 21 (15.3%) had a PsA diagnosis. Final regression model retained four independent items, including evocative signs of dactylitis, inflammatory heel pain, bilateral buttock pain and peripheral joint pain with swelling in patients aged <50. A total score (the PURE-4) was computed (0-4 points) that demonstrated excellent discriminative power (AUC = 87.6%; Sensitivity = 85.7% and Specificity = 83.6% at the threshold of ≥1/4 points), with no evidence for over-optimism in bootstrapped internal validation., Conclusion: These findings demonstrate the good diagnostic properties of a new screening scale using only four easy-to-collect items. If confirmed in other populations, it may prove useful in outpatient dermatology clinics for triage of psoriasis patients requiring further assessment by the rheumatologist., (© 2018 European Academy of Dermatology and Venereology.)
- Published
- 2018
- Full Text
- View/download PDF
36. Rachialgie : un motif fréquent de consultation.
- Author
-
Hilliquin P and Nang M
- Abstract
Competing Interests: P. Hilliquin et M. Nang déclarent n’avoir aucun lien d’intérêts.
- Published
- 2016
37. Rachialgie.
- Author
-
Hilliquin P and Nang M
- Abstract
Competing Interests: P. Hilliquin et M. Nang déclarent n’avoir aucun lien d’intérêts.
- Published
- 2016
38. [What's new in rheumatology].
- Author
-
Hilliquin P and Zalc J
- Subjects
- Rheumatology trends
- Abstract
Competing Interests: Les auteurs déclarent n’avoir aucun lien d’intérêts.
- Published
- 2016
39. Glucocorticoid-sparing in patients suffering from rheumatoid arthritis and treated with tocilizumab: the SPARE-1 study.
- Author
-
Saraux A, Rouanet S, Flipo RM, Poncet JC, Fardellone P, Hilliquin P, Idier I, and Cantagrel A
- Subjects
- Adult, Aged, Antirheumatic Agents therapeutic use, Female, Humans, Male, Middle Aged, Prospective Studies, Antibodies, Monoclonal, Humanized therapeutic use, Arthritis, Rheumatoid drug therapy, Prednisone therapeutic use
- Abstract
Objectives: To describe steroid-sparing in rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ)., Methods: To evaluate the proportion of RA patients treated with more than 5 mg of prednisone (or equivalent)/day and starting TCZ who can receive less than 5 mg/day after 12 months without intensification of disease-modifying anti-rheumatic drugs (DMARDs), we conducted a non-interventional, multicentre, prospective study from 2011 to 2013. We included patients with moderate-to-severe RA, >18 years old, starting TCZ and receiving corticosteroids (GCs) at a dose greater than 5 mg/day of prednisone for at least 3 months., Results: Amongst the 307 analysed patients (78% women, median RA duration: 8 years, mean DAS28-ESR: 5.1±1.3), 40% (95%CI=[35-46]) reached the targeted daily prednisone dose at M12, without conventional synthetic (cs)DMARD intensification. Predictive factors were RA duration of 5 years or less (OR=2.60, p=0.01), daily prednisone dose of 7.5 mg or less (OR=2.12, p=0.03), and low ESR value before the first TCZ infusion (OR=0.86, p=0.047). The proportion of patients with no more GCs increased up to 20% at M12. Disease activity improved over the 1-year period (DAS28-ESR LDA and remission in 41% and 33% of patients at M12, respectively). Amongst the 314 patients analysed for safety, at least one AE and at least one SAE were reported in 211 patients (67%) and in 48 patients (15%), respectively. No unexplained safety signal arose with TCZ., Conclusions: A biological DMARD as TCZ allows reducing both GCs dose and disease activity in RA patients. Nevertheless, corticosteroid spare in real life is probably lower.
- Published
- 2016
40. Relationship between SNPs and expression level for candidate genes in rheumatoid arthritis.
- Author
-
Fodil M, Teixeira VH, Chaudru V, Hilliquin P, Bombardieri S, Balsa A, Westhovens R, Barrera P, Alves H, Migliorin P, Bardin T, Cornelis F, Boudjema A, and Petit-Teixeira E
- Subjects
- Adult, Calgranulin A genetics, Core Binding Factor Alpha 3 Subunit genetics, Female, Genetic Markers, Genotype, Humans, Interleukin-2 Receptor beta Subunit genetics, Lymphocyte Antigen 96 genetics, Male, Middle Aged, Young Adult, Arthritis, Rheumatoid genetics, Cytokines genetics, Eosinophil-Derived Neurotoxin genetics, Genetic Predisposition to Disease, Polymorphism, Single Nucleotide, Transcriptome
- Abstract
Objectives: The study of polymorphisms of genes differentially expressed may lead to the identification of putative causal genetic variants in multifactorial diseases such as rheumatoid arthritis (RA). Based on preceding transcriptomic results, we genotyped 10 single nucleotide polymorphisms (SNPs) belonging to six genes (S100A8, RNASE2, PGLYRP1, RUNX3, IL2RB, and LY96) showing the highest fold change (> 1.9) when level of expression was compared between RA patients and controls. These SNPs were then analysed to evaluate their role in RA., Method: The relationship between gene expression and genotypes of SNPs was first investigated by Kruskal-Wallis and Mann-Whitney tests in RA patients and controls. The genetic association of these SNPs with RA were then analysed using family-based association tests in trio families., Results: We found that RNASE2 gene expression was related to rs2013109 genotypes in 14 RA patients (p = 0.030). The association study in a discovery sample of 200 French trio families revealed a significant association with RA for one SNP, PGLYRP1-rs2041992 (p = 0.019); this association was stronger in trios where RA patients carried the HLA-DRB1 shared epitope (SE) (p = 0.003). However, this association was not found in a replication sample of 240 European trio families (p = 0.6)., Conclusions: Family-based association tests did not reveal an association between RA and any SNP of the candidate genes tested. However, RNASE2 gene expression was differentially expressed in RA patients considering a sequence polymorphism. This result led us to highlight the potential disease-specific regulation for this candidate gene in RA.
- Published
- 2015
- Full Text
- View/download PDF
41. Autoimmune disorders and quadrivalent human papillomavirus vaccination of young female subjects.
- Author
-
Grimaldi-Bensouda L, Guillemot D, Godeau B, Bénichou J, Lebrun-Frenay C, Papeix C, Labauge P, Berquin P, Penfornis A, Benhamou PY, Nicolino M, Simon A, Viallard JF, Costedoat-Chalumeau N, Courcoux MF, Pondarré C, Hilliquin P, Chatelus E, Foltz V, Guillaume S, Rossignol M, and Abenhaim L
- Subjects
- Adolescent, Adult, Alphapapillomavirus, Autoimmune Diseases epidemiology, Autoimmune Diseases etiology, Case-Control Studies, Connective Tissue Diseases immunology, Diabetes Mellitus, Type 1 immunology, Female, France epidemiology, Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18, Humans, Incidence, Multiple Sclerosis immunology, Papillomavirus Infections immunology, Papillomavirus Vaccines administration & dosage, Purpura, Thrombocytopenic, Idiopathic immunology, Risk Factors, Young Adult, Autoimmune Diseases immunology, Mass Vaccination statistics & numerical data, Papillomavirus Infections prevention & control, Papillomavirus Vaccines adverse effects
- Abstract
Objectives: The aim of this study was to investigate whether the quadrivalent human papillomavirus (HPV) vaccine Gardasil is associated with a change in the risk of autoimmune disorders (ADs) in young female subjects., Design: Systematic case-control study of incident ADs associated with quadrivalent HPV vaccination in young women across France., Participants and Setting: A total of 113 specialised centres recruited (from December 2007 to April 2011) females aged 14-26 years with incident cases of six types of ADs: idiopathic thrombocytopenic purpura (ITP), central demyelination/multiple sclerosis (MS), Guillain-Barré syndrome, connective tissue disorders (systemic lupus erythematosus, rheumatoid arthritis/juvenile arthritis), type 1 diabetes mellitus and autoimmune thyroiditis. Control subjects matched to cases were recruited from general practice., Analysis: Multivariate conditional logistic regression analysis; factors included age, geographical origin, smoking, alcohol consumption, use of oral contraceptive(s) or vaccine(s) other than Gardasil received within 24 months before the index date and personal/family history of ADs., Results: Overall, 211 definite cases of ADs were matched to 875 controls. The adjusted odds ratio (OR) for any quadrivalent HPV vaccine use was 0.9 [95% confidence interval (CI) 0.5-1.5]. The individual ORs were 1.0 (95% CI 0.4-2.6) for ITP, 0.3 (95% CI 0.1-0.9) for MS, 0.8 (95% CI 0.3-2.4) for connective disorders and 1.2 (95% CI 0.4-3.6) for type 1 diabetes. No exposure to HPV vaccine was observed in cases with either Guillain-Barré syndrome or thyroiditis., Conclusions: No evidence of an increase in the risk of the studied ADs was observable following vaccination with Gardasil within the time periods studied. There was insufficient statistical power to allow conclusions to be drawn regarding individual ADs., (© 2013 The Association for the Publication of the Journal of Internal Medicine.)
- Published
- 2014
- Full Text
- View/download PDF
42. Early effect of hyaluronic acid intra-articular injections on serum and urine biomarkers in patients with knee osteoarthritis: An open-label observational prospective study.
- Author
-
Conrozier T, Balblanc JC, Richette P, Mulleman D, Maillet B, Henrotin Y, Rannou F, Piroth C, Hilliquin P, Mathieu P, Walliser-Lohse A, Rousselot I, Plattner V, Maillefert JF, Vignon E, and Chevalier X
- Subjects
- Aged, Biomarkers urine, Female, Humans, Injections, Intra-Articular, Male, Middle Aged, Osteoarthritis, Knee blood, Osteoarthritis, Knee urine, Prospective Studies, Biomarkers blood, Hyaluronic Acid administration & dosage, Osteoarthritis, Knee drug therapy, Viscosupplementation, Viscosupplements administration & dosage
- Abstract
The aim of the study was to investigate the effect of hyaluronic acid (HA) intra articular injections (IA) on osteoarthritis (OA) biomarkers in patients with knee OA. Prospective open label study. Fifty-one patients with unilateral symptomatic K-OA received IA injections of 2mL of HA on days (D) 1, 7, 14 and were followed 3 months. At D-15 patients were examined and X-rays performed, to exclude patients with bilateral K-OA, or those with more than three symptomatic OA joints. From 15 days (D-15) before the first injection to D90 concomitant therapies were unchanged. Walking pain (WP) on VAS was obtained at each visit. Urine (U) and serum (S) samples were obtained at D-15, D1, D30, and D90. S-C2C, S-Cartilage oligomeric matrix protein, S-HA, S-CS 846 epitope, S-type II collagen propeptide, and U-type II collagen C telopeptide (U-CTX II/creatinin) were assayed. Predictive factors of response were analyzed using logistic regression. Correlations between variables were obtained using Spearman test. Forty-five patients were analyzed. Between D-15 and D1 there was no difference for any biomarkers At D1, WP (SD) was correlated with U-CTX II/creat (p = 0.006). Between D1 and D90: U-CTX II/creat decreased significantly. After adjustment for confounding variables there was a significant correlation between clinical response and U-CTX II/creat variation. U-CTX II and S-HA at baseline were independently predictive of clinical response. This study showed that 90 days after HA IA injections, U-CTX II levels significantly decrease compared to baseline, suggesting a slowdown of type II collagen degradation., (Copyright © 2011 Orthopaedic Research Society.)
- Published
- 2012
- Full Text
- View/download PDF
43. Onset of action of etanercept in rheumatoid arthritis based on patient-reported outcomes.
- Author
-
Dougados M, Ripert M, Hilliquin P, Brocq O, Brault Y, and Logeart I
- Subjects
- Adult, Aged, Analysis of Variance, Arthritis, Rheumatoid diagnosis, Arthritis, Rheumatoid psychology, Disability Evaluation, Etanercept, Female, Humans, Kaplan-Meier Estimate, Male, Middle Aged, Paris, Patients psychology, Perception, Predictive Value of Tests, Prospective Studies, Severity of Illness Index, Surveys and Questionnaires, Time Factors, Treatment Outcome, Antirheumatic Agents therapeutic use, Arthritis, Rheumatoid drug therapy, Immunoglobulin G therapeutic use, Receptors, Tumor Necrosis Factor therapeutic use
- Abstract
Background: Onset of action is considered to be a key characteristic of the treatment of rheumatoid arthritis. The efficacy of TNF blockers is usually evaluated after 2 to 4 weeks of therapy. EULAR-RAID is a valid patient-reported outcome composite index., Objectives: To evaluate the onset of action of etanercept in rheumatoid arthritis patients according to the EULAR-RAID score., Methods: An open-label, single-arm (etanercept 50 mg/week), 12-week study was carried out in patients with active rheumatoid arthritis. Patients were asked to fill in the RAID score questionnaire each day for the first 14 days of the study and at the 4-week and 12-week visits. Onset of action was evaluated by considering: a) changes over time of the EULAR-RAID score; b) the percentage of patients achieving an 'acceptable' condition according to the EULAR-RAID score (e.g. a score ≤3.00)., Results: Of the 120 screened patients, 108 (female: 75%), age 54±13 years, disease duration 8±7 years) were enrolled. At baseline, patients had active rheumatoid arthritis (DAS: 5.4±0.8; CRP: 18.±30mg/l). Eleven patients dropped out of the study. A statistically significant decrease in the EULAR-RAID score was observed by day 1 of therapy. Kaplan-Meier estimates of the proportion of patients achieving an acceptable RAID score were 29.8 [% 95% C.I. 23.8-X42.6], 50 % [95% C.I. 41-60.9], 51.9% [95% C.I. 43.8-63.7], 56% [95% C.I. 49.5-69.1, after 1, 2, 4 and 12 weeks of therapy respectively. The median time to achieve an acceptable EULAR-RAID score was 14.5 days., Conclusions: This open-label study suggests that patients can perceive a clinically relevant improvement by the first week of etanercept therapy.
- Published
- 2012
44. Comparison of general practitioners and rheumatologists' prescription patterns for patients with knee osteoarthritis.
- Author
-
Richette P, Hilliquin P, Bertin P, Carni P, Berger V, and Marty M
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Arthralgia prevention & control, Disability Evaluation, Humans, Pain Measurement methods, Pain Measurement trends, Prospective Studies, Surveys and Questionnaires standards, Arthralgia drug therapy, General Practitioners trends, Osteoarthritis, Knee drug therapy, Practice Patterns, Physicians' trends, Rheumatology trends
- Abstract
Background: To compare the prescription modalities of general practitioners (GPs) and rheumatologists (RHs) for symptomatic knee osteoarthritis (OA) and to determine correlates with prescription of low-dose NSAIDs., Methods: This observational, prospective, national survey was carried out among a national representative sample of GPs (n = 808) and RHs (n = 134). Each physician completed a medical questionnaire for the 2 most recent patients fulfilling the ACR criteria for knee OA., Results: GPs and RHs included 1,570 and 251 patients, respectively. Mean pain level of the knee (on a VAS, 0-100 mm) was greater for GP patients than for RH patients (49.8 ± 16.3 vs. 46.2 ± 17.1 mm, respectively; p < 0.01). As compared with patients of RHs, those of GPs more frequently had another joint affected by OA: 71.2% vs. 63.7% (p < 0.0001) and more often had hypertension and diabetes mellitus (p < 0.05). As compared with RHs, GPs more frequently prescribed low-dose NSAIDs (p < 0.0001), oral NSAIDs (p < 0.05), and topical NSAIDs (p < 0.0001) but less frequently symptomatic slow-acting drugs for OA (p < 0.01). Moreover, GPs more frequently recommended rehabilitation (p < 0.01) and loss of weight (p < 0.0001). Logistic regression analysis revealed an association of low-dose NSAIDs prescription and prescription by GPs, prescription of topical NSAIDs, no prescription of oral NSAIDs or coxibs and no intra-articular injection of steroids., Conclusions: This study identified speciality-related variability in some aspects of the management of knee OA. The clinical profile of patients with knee OA differed between GPs and RHs.
- Published
- 2011
- Full Text
- View/download PDF
45. Management recommendations for knee osteoarthritis: how usable are they?
- Author
-
Poitras S, Rossignol M, Avouac J, Avouac B, Cedraschi C, Nordin M, Rousseaux C, Rozenberg S, Savarieau B, Thoumie P, Valat JP, Vignon E, and Hilliquin P
- Subjects
- Acetaminophen therapeutic use, Aged, Aged, 80 and over, Analgesics, Non-Narcotic therapeutic use, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Attitude to Health, Disease Management, Female, General Practice, Guideline Adherence, Humans, Male, Middle Aged, Osteoarthritis, Knee drug therapy, Osteoarthritis, Knee rehabilitation, Patient Compliance, Physical Exertion, Physical Therapy Modalities, Practice Guidelines as Topic, Practice Patterns, Physicians', Weight Loss, Osteoarthritis, Knee therapy
- Abstract
Objectives: Despite the availability of practice guidelines for the management of knee osteoarthritis, inadequacies in practices of clinicians and patients have been found, leading to suboptimal outcomes. Literature has shown that simply disseminating management recommendations does not lead to adherence. Research suggests that barriers to use should be identified and addressed to improve adherence. The objective of this study was to identify barriers to use of conservative management recommendations for knee osteoarthritis by patients, general practitioners and physiotherapists., Methods: Following systematic reviews of evidence and guidelines, 12 key management recommendations were elaborated on four themes: medication, exercise, self-management and occupation. Focus groups were separately done with patients with knee osteoarthritis, general practitioners and physiotherapists to assess barriers to the use of recommendations., Results: Patients and general practitioners appeared generally fatalistic with regards to knee osteoarthritis, with physiotherapists being more positive regarding long-term improvement of knee osteoarthritis. For medication, discrepancies were found between recommendations and views of clinicians. Both patients and general practitioners appeared ambivalent towards exercise and activity, recognizing its usefulness but identifying it at the same time as a cause of knee osteoarthritis. Patients and general practitioners appeared to consider weight loss particularly difficult., Discussion/conclusions: Barriers specific to each knee osteoarthritis management recommendation and stakeholder group were identified. Recommendations to address these barriers were elaborated. Results of this study can be used to develop implementation strategies to overcome identified barriers, with the goal of facilitating the use of guideline recommendations and improving outcomes., (Copyright © 2010 Société française de rhumatologie. Published by Elsevier SAS. All rights reserved.)
- Published
- 2010
- Full Text
- View/download PDF
46. Transcriptome analysis describing new immunity and defense genes in peripheral blood mononuclear cells of rheumatoid arthritis patients.
- Author
-
Teixeira VH, Olaso R, Martin-Magniette ML, Lasbleiz S, Jacq L, Oliveira CR, Hilliquin P, Gut I, Cornelis F, and Petit-Teixeira E
- Subjects
- Arthritis, Rheumatoid genetics, Down-Regulation, Female, Gene Expression Profiling, Humans, Male, Middle Aged, Polymerase Chain Reaction, Up-Regulation, Arthritis, Rheumatoid blood, Monocytes pathology, RNA, Messenger genetics
- Abstract
Background: Large-scale gene expression profiling of peripheral blood mononuclear cells from Rheumatoid Arthritis (RA) patients could provide a molecular description that reflects the contribution of diverse cellular responses associated with this disease. The aim of our study was to identify peripheral blood gene expression profiles for RA patients, using Illumina technology, to gain insights into RA molecular mechanisms., Methodology/principal Findings: The Illumina Human-6v2 Expression BeadChips were used for a complete genome-wide transcript profiling of peripheral blood mononuclear cells (PBMCs) from 18 RA patients and 15 controls. Differential analysis per gene was performed with one-way analysis of variance (ANOVA) and P values were adjusted to control the False Discovery Rate (FDR<5%). Genes differentially expressed at significant level between patients and controls were analyzed using Gene Ontology (GO) in the PANTHER database to identify biological processes. A differentially expression of 339 Reference Sequence genes (238 down-regulated and 101 up-regulated) between the two groups was observed. We identified a remarkably elevated expression of a spectrum of genes involved in Immunity and Defense in PBMCs of RA patients compared to controls. This result is confirmed by GO analysis, suggesting that these genes could be activated systemically in RA. No significant down-regulated ontology groups were found. Microarray data were validated by real time PCR in a set of nine genes showing a high degree of correlation., Conclusions/significance: Our study highlighted several new genes that could contribute in the identification of innovative clinical biomarkers for diagnostic procedures and therapeutic interventions.
- Published
- 2009
- Full Text
- View/download PDF
47. Validation of the KOFUS (Knee Osteoarthritis Flare-Ups Score).
- Author
-
Marty M, Hilliquin P, Rozenberg S, Valat JP, Vignon E, Coste P, Savarieau B, and Allaert FA
- Subjects
- Aged, Cross-Sectional Studies, Databases, Factual, Female, Health Status, Humans, Knee Joint physiopathology, Logistic Models, Male, Middle Aged, Osteoarthritis, Knee physiopathology, Predictive Value of Tests, ROC Curve, Reproducibility of Results, Severity of Illness Index, Osteoarthritis, Knee diagnosis, Professional Practice statistics & numerical data, Rheumatology methods
- Abstract
Objective: To develop a diagnostic score for knee osteoarthritis flare-ups and to evaluate its sensitivity and specificity., Methods: We used two epidemiological databases built using the same methodology. One database was from a general-practice study and served to develop the score, whereas the other was from a rheumatology study and served to validate the score. Physicians determined the flare-up status of each patient. The rheumatologist diagnosis was the reference standard. Logistic regression was performed to identify factors significantly associated with having a flare-up., Results: Of the 6085 patients in the general-practice database, 52.3% had a knee osteoarthritis flare-up. The score was built by assigning points to features that were present, with a weighting system based on the odds ratio of each feature for having a flare-up (0, feature absent; 1, morning stiffness for longer than 20 min; 2, pain causing nocturnal awakenings and knee effusion; 3, limping, joint swelling, and increased warmth over the knee). The score could range from 0 to 14. The receiver-operating characteristic curve showed that 7 was the best cutoff for diagnosing a flare-up. In the rheumatologist database, the numbers of patients having a flare-up were 274 (46.4%) based on the score and 270 (45.7%) based on the rheumatologist diagnosis. Sensitivity of the score was 87.0%, specificity 87.9%, positive predictive value 85.8%, and negative predictive value 89.0%. The Youden index was 0.75., Conclusion: A score equal to or greater than 7 points correlated well with a rheumatologist diagnosis of flare-up. Our score may constitute a valid objective criterion for standardizing the diagnosis of knee osteoarthritis flare-up, most notably when screening patients for inclusion in therapeutic trials.
- Published
- 2009
- Full Text
- View/download PDF
48. Paget's disease of bone in the French population: novel SQSTM1 mutations, functional analysis, and genotype-phenotype correlations.
- Author
-
Collet C, Michou L, Audran M, Chasseigneaux S, Hilliquin P, Bardin T, Lemaire I, Cornélis F, Launay JM, Orcel P, and Laplanche JL
- Subjects
- Adaptor Proteins, Signal Transducing, Base Sequence, Blotting, Western, Cell Line, Transformed, DNA Primers, France epidemiology, Genotype, Humans, Osteitis Deformans genetics, Phenotype, Sequestosome-1 Protein, Mutation, Osteitis Deformans epidemiology, Proteins genetics
- Abstract
Unlabelled: Mutation screening of the SQSTM1 gene in 94 French patients with PDB revealed two novel point-mutations (A381V and L413F) and two new compound heterozygous genotypes (P392L/A381V and P392L/A390X). Functional analysis showed an increased level of SQSTM1/p62 protein in PDB patients and truncated forms of the protein encoded by the A390X allele. Clinical data indicate that PDB patients with SQSTM1 mutation are younger at PDB diagnosis and have more extensive bone lesions., Introduction: Paget's disease of bone (PDB) is a common chronic disease of the skeleton, with a strong genetic component. A recurrent mutation (P392L) was first identified on chromosome 5, in the Sequestosome 1 (SQSTM1) gene. Several other mutations of the SQSTM1 gene have been described in PDB patients, affecting the ubiquitin-associated domain (UBA) of the SQSTM1/p62 protein. The objectives of this study were to evaluate the frequency of the SQSTM1 mutations in French PBD patients, to study the expression of the SQSTM1/p62 protein, and to search for genotype-phenotype correlations., Materials and Methods: Blood was obtained from 94 unrelated French PDB patients and 100 controls for mutation screening of exons 7 and 8, encoding for the UBA domain of SQSTM1. Epstein-Barr virus (EBV)-immortalized B-cell lymphocytes were established from 13 patients, giving access to functional analysis of the gene and the SQSTM1/p62 expressions using real-time PCR and Western blot., Results: Mutations of the SQSTM1 gene were identified in 12 of the 94 PDB patients (13%). Eight patients carried P392L. Two novel missense mutations were identified: L413F and A381V. This A381V mutation and A390X were found in distinct patients already carriers of P392L. The SQSTM1/p62 protein expression in PDB patients increased when zero, one, or two mutations were present, and SQSTM1 truncated forms were associated with the A390X mutation. The mean age of PDB diagnosis was younger in patients with the SQSTM1 mutation. PDB was more extensive in patients who carried a SQSTM1 mutation., Conclusions: Mutations of SQSTM1 are present in the French population. PDB patients with and without the SQSTM1 mutation have an increased level of SQSTM1/p62, caused by overproduction of the protein, probably involved in the pathophysiology of PDB. The presence of the SQSTM1 mutation may be a worsening factor for PDB.
- Published
- 2007
- Full Text
- View/download PDF
49. The ITGAV rs3738919-C allele is associated with rheumatoid arthritis in the European Caucasian population: a family-based study.
- Author
-
Jacq L, Garnier S, Dieudé P, Michou L, Pierlot C, Migliorini P, Balsa A, Westhovens R, Barrera P, Alves H, Vaz C, Fernandes M, Pascual-Salcedo D, Bombardieri S, Dequeker J, Radstake TR, Van Riel P, van de Putte L, Lopes-Vaz A, Glikmans E, Barbet S, Lasbleiz S, Lemaire I, Quillet P, Hilliquin P, Teixeira VH, Petit-Teixeira E, Mbarek H, Prum B, Bardin T, and Cornélis F
- Subjects
- Adult, Arthritis, Rheumatoid ethnology, DNA Mutational Analysis, Europe ethnology, Family Health ethnology, Female, Gene Frequency, Humans, Linkage Disequilibrium, Male, Polymerase Chain Reaction, Alleles, Arthritis, Rheumatoid genetics, Genetic Predisposition to Disease, Integrin alphaV genetics, Polymorphism, Single Nucleotide, White People genetics
- Abstract
The integrin alpha(v)beta3, whose alpha(v) subunit is encoded by the ITGAV gene, plays a key role in angiogenesis. Hyperangiogenesis is involved in rheumatoid arthritis (RA) and the ITGAV gene is located in 2q31, one of the suggested RA susceptibility loci. Our aim was to test the ITGAV gene for association and linkage to RA in a family-based study from the European Caucasian population. Two single nucleotide polymorphisms were genotyped by PCR-restriction fragment length polymorphism in 100 French Caucasian RA trio families (one RA patient and both parents), 100 other French families and 265 European families available for replication. The genetic analyses for association and linkage were performed using the comparison of allelic frequencies (affected family-based controls), the transmission disequilibrium test, and the genotype relative risk.We observed a significant RA association for the C allele of rs3738919 in the first sample (affected family-based controls, RA index cases 66.5% versus controls 56.7%; P = 0.04). The second sample showed the same trend, and the third sample again showed a significant RA association. When all sets were combined, the association was confirmed (affected family-based controls, RA index cases 64.6% versus controls 58.1%; P = 0.005). The rs3738919-C allele was also linked to RA (transmission disequilibrium test, 56.5% versus 50% of transmission; P = 0.009) and the C-allele-containing genotype was more frequent in RA index cases than in controls (RA index cases 372 versus controls 339; P = 0.002, odds ratio = 1.94, 95% confidence interval = 1.3-2.9). The rs3738919-C allele of the ITGAV gene is associated with RA in the European Caucasian population, suggesting ITGAV as a new minor RA susceptibility gene.
- Published
- 2007
- Full Text
- View/download PDF
50. A critical appraisal of guidelines for the management of knee osteoarthritis using Appraisal of Guidelines Research and Evaluation criteria.
- Author
-
Poitras S, Avouac J, Rossignol M, Avouac B, Cedraschi C, Nordin M, Rousseaux C, Rozenberg S, Savarieau B, Thoumie P, Valat JP, Vignon E, and Hilliquin P
- Subjects
- Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Exercise Therapy, Humans, Osteoarthritis, Knee drug therapy, Osteoarthritis, Knee surgery, Patient Education as Topic, Osteoarthritis, Knee therapy, Practice Guidelines as Topic standards
- Abstract
Clinical practice guidelines have been elaborated to summarize evidence related to the management of knee osteoarthritis and to facilitate uptake of evidence-based knowledge by clinicians. The objectives of the present review were summarizing the recommendations of existing guidelines on knee osteoarthritis, and assessing the quality of the guidelines using a standardized and validated instrument--the Appraisal of Guidelines Research and Evaluation (AGREE) tool. Internet medical literature databases from 2001 to 2006 were searched for guidelines, with six guidelines being identified. Thirteen clinician researchers participated in the review. Each reviewer was trained in the AGREE instrument. The guidelines were distributed to four groups of three or four reviewers, each group reviewing one guideline with the exception of one group that reviewed two guidelines. One independent evaluator reviewed all guidelines. All guidelines effectively addressed only a minority of AGREE domains. Clarity/presentation was effectively addressed in three out of six guidelines, scope/purpose and rigour of development in two guidelines, editorial independence in one guideline, and stakeholder involvement and applicability in none. The clinical management recommendation tended to be similar among guidelines, although interventions addressed varied. Acetaminophen was recommended for initial pain treatment, combined with exercise and education. Nonsteroidal anti-inflammatory drugs were recommended if acetaminophen failed to control pain, but cautiously because of gastrointestinal risks. Surgery was recommended in the presence of persistent pain and disability. Education and activity management interventions were superficially addressed in most guidelines. Guideline creators should use the AGREE criteria when developing guidelines. Innovative and effective methods of knowledge translation to health professionals are needed.
- Published
- 2007
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.